METHOTREXATE LPF: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hospira	METHOTREXATE LPF	methotrexate sodium	INJECTABLE;INJECTION	011719	NDA	Hospira, Inc.	61703-124-40	1 VIAL, SINGLE-DOSE in 1 CARTON (61703-124-40) / 40 mL in 1 VIAL, SINGLE-DOSE	2022-10-17
Hospira	METHOTREXATE LPF	methotrexate sodium	INJECTABLE;INJECTION	011719	NDA	Hospira, Inc.	61703-161-05	5 VIAL, MULTI-DOSE in 1 CARTON (61703-161-05) / 2 mL in 1 VIAL, MULTI-DOSE (61703-161-02)	2024-11-04
Hospira	METHOTREXATE LPF	methotrexate sodium	INJECTABLE;INJECTION	011719	NDA	Hospira, Inc.	61703-350-10	5 VIAL, MULTI-DOSE in 1 CARTON (61703-350-10) / 2 mL in 1 VIAL, MULTI-DOSE (61703-350-09)	2014-09-25
Hospira	METHOTREXATE LPF	methotrexate sodium	INJECTABLE;INJECTION	011719	NDA	Hospira, Inc.	61703-350-38	5 VIAL, MULTI-DOSE in 1 CARTON (61703-350-38) / 2 mL in 1 VIAL, MULTI-DOSE (61703-350-37)	2014-09-25
Hospira	METHOTREXATE LPF	methotrexate sodium	INJECTABLE;INJECTION	011719	NDA	Hospira, Inc.	61703-350-10	5 VIAL, MULTI-DOSE in 1 CARTON (61703-350-10) / 2 mL in 1 VIAL, MULTI-DOSE (61703-350-09)	2005-07-27
Hospira	METHOTREXATE LPF	methotrexate sodium	INJECTABLE;INJECTION	011719	NDA	Hospira, Inc.	61703-350-38	5 VIAL, MULTI-DOSE in 1 CARTON (61703-350-38) / 2 mL in 1 VIAL, MULTI-DOSE (61703-350-37)	2005-07-27
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis examines the global supply landscape for Methotrexate LPF (Low-Molecular-Weight Phenolic), a critical component in pharmaceutical manufacturing. The report identifies key suppliers, their production capacities, regulatory standing, and potential supply chain risks. Understanding these elements is crucial for pharmaceutical companies to ensure consistent production, mitigate sourcing disruptions, and maintain competitive advantage.

WHAT IS METHOTREXATE LPF AND ITS PHARMACEUTICAL APPLICATIONS?

Methotrexate LPF is a synthesized folic acid antagonist used primarily in the treatment of certain types of cancer, including leukemia, lymphoma, and solid tumors. It also serves as an immunosuppressive agent for autoimmune diseases such as rheumatoid arthritis and psoriasis. Its mechanism of action involves inhibiting dihydrofolate reductase, an enzyme essential for DNA synthesis, thereby halting the proliferation of rapidly dividing cells, including cancer cells and overactive immune cells.

The pharmaceutical industry utilizes Methotrexate LPF as an Active Pharmaceutical Ingredient (API). Its production requires stringent quality control measures to meet pharmacopeial standards. Key therapeutic applications include:

Oncology: Acute lymphoblastic leukemia, non-Hodgkin lymphoma, osteosarcoma, breast cancer, head and neck cancer.
Rheumatology: Severe active rheumatoid arthritis, psoriatic arthritis.
Dermatology: Severe recalcitrant plaque psoriasis.

The global demand for Methotrexate LPF is driven by the prevalence of these conditions and the drug's established efficacy and cost-effectiveness.

WHO ARE THE PRIMARY GLOBAL MANUFACTURERS OF METHOTREXATE LPF?

The production of Methotrexate LPF is concentrated among a limited number of specialized API manufacturers. These companies possess the technical expertise and regulatory compliance necessary for its synthesis.

The identified key manufacturers include:

Altan Pharmaceutical (Turkey): Altan Pharmaceutical is a significant producer of APIs, including Methotrexate LPF. The company operates state-of-the-art manufacturing facilities compliant with Good Manufacturing Practices (GMP). Their capacity is estimated to be substantial, serving both domestic and international markets.
Biopharm (Iran): Biopharm is another prominent supplier of Methotrexate LPF. The company has invested in advanced production technologies and maintains a strong regulatory profile, adhering to international standards. Their output contributes significantly to the global supply.
Cipla Limited (India): Cipla is a major Indian pharmaceutical company with a diverse API portfolio. They manufacture Methotrexate LPF, leveraging their extensive manufacturing infrastructure and robust quality assurance systems. Cipla's global reach ensures broad market accessibility.
Hospira, Inc. (now part of Pfizer) (United States): While Hospira was a key player, its acquisition by Pfizer has integrated its operations. Pfizer, as the parent entity, continues to be a source of Methotrexate LPF, albeit with potentially consolidated manufacturing strategies. Their historical role and continued presence signify established production capabilities.
Jubilant Life Sciences (India): Jubilant is a global integrated pharmaceutical company that manufactures APIs for a wide range of therapeutic areas. Methotrexate LPF is part of their API offerings, produced under strict quality controls.
MSN Laboratories (India): MSN Laboratories is an emerging force in API manufacturing, known for its scalable production and commitment to quality. They are a notable supplier of Methotrexate LPF, increasing competition in the market.
Pharmarock (China): Pharmarock is a Chinese manufacturer that produces Methotrexate LPF. China has a substantial API manufacturing base, and Pharmarock contributes to this global supply. Compliance with international standards is a key factor for their market penetration.
Sun Pharma (India): Sun Pharma is one of the largest pharmaceutical companies globally, with significant API manufacturing capabilities. They produce Methotrexate LPF, benefiting from their broad operational scale and established supply chain networks.
Takeda Pharmaceutical Company (Japan): While Takeda is primarily known for its finished drug products, it also possesses API manufacturing capabilities. Their involvement in Methotrexate LPF production, though perhaps less prominent than dedicated API manufacturers, contributes to supply diversity.

What is the geographical distribution of these manufacturers?

The manufacturing base for Methotrexate LPF is distributed across several key regions, reflecting global pharmaceutical supply chain dynamics.

India: This region hosts multiple significant manufacturers, including Cipla, Jubilant Life Sciences, MSN Laboratories, and Sun Pharma. India is a dominant force in global API production due to its cost-effective manufacturing, skilled workforce, and established regulatory framework.
Turkey: Altan Pharmaceutical is a primary contributor from this region, showcasing a growing presence in specialized API markets.
Iran: Biopharm represents Iran's contribution to the global Methotrexate LPF supply, operating with international quality standards.
United States: Historically through Hospira and now under Pfizer, the U.S. maintains a presence in high-value API manufacturing, often focusing on complex synthesis and stringent regulatory compliance.
China: Pharmarock signifies China's role as a major API producer. China's extensive chemical manufacturing infrastructure supports its significant output of various APIs.
Japan: Takeda Pharmaceutical Company represents Japan's participation, often associated with high-quality, innovation-driven pharmaceutical production.

This geographical dispersion offers a degree of resilience, but also creates potential vulnerabilities related to geopolitical stability, trade policies, and regional regulatory differences.

WHAT ARE THE PRODUCTION CAPACITIES AND POTENTIAL BOTTLENECKS?

Estimating precise production capacities for APIs like Methotrexate LPF is challenging due to proprietary information. However, based on company profiles, market presence, and industry reports, general assessments can be made.

Manufacturers in India, due to their scale and the number of active players, likely hold the largest aggregate production capacity. Companies like Cipla, Sun Pharma, and Jubilant operate large-scale facilities. Chinese manufacturers also contribute significantly to global volume.

Potential bottlenecks in Methotrexate LPF supply can arise from several factors:

Raw Material Sourcing: The synthesis of Methotrexate LPF relies on specific chemical precursors. Disruptions in the supply of these intermediates, whether due to geopolitical issues, environmental regulations, or production issues at upstream suppliers, can impact final API output. For example, the availability of key starting materials like para-aminobenzoylglutamic acid or 4-((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoic acid derivatives can become a constraint.
Regulatory Compliance: Manufacturing facilities must adhere to strict GMP standards and undergo regular inspections by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. A facility failing an inspection or facing a product recall can immediately reduce available supply. Manufacturers must maintain ongoing compliance, which requires significant investment in quality systems and personnel.
Geopolitical Factors: Trade disputes, tariffs, and political instability in regions with significant manufacturing presence can disrupt supply chains. For instance, sanctions or export restrictions affecting countries like Iran or China could limit the availability of Methotrexate LPF from those sources.
Environmental Regulations: Increasingly stringent environmental regulations in manufacturing hubs like China and India can lead to temporary or permanent plant shutdowns for non-compliant facilities, impacting overall production capacity.
Consolidation and Mergers: As seen with Hospira and Pfizer, industry consolidation can lead to the streamlining of production lines, potentially reducing redundancy and concentrating manufacturing in fewer, larger sites. While this can improve efficiency, it can also create single points of failure.
Logistical Challenges: The global transportation of APIs is subject to shipping delays, customs issues, and increased freight costs, particularly in volatile economic periods or during global crises.

WHAT IS THE REGULATORY STATUS AND QUALITY CONTROL FRAMEWORK FOR METHOTREXATE LPF?

The production and supply of Methotrexate LPF are governed by a comprehensive regulatory framework designed to ensure product safety, efficacy, and quality.

Key regulatory aspects include:

Good Manufacturing Practices (GMP): All manufacturers must comply with GMP guidelines established by major regulatory authorities. These guidelines cover all aspects of production, from raw material sourcing and facility design to personnel training, process validation, and quality control. For Methotrexate LPF, adherence to USP (United States Pharmacopeia), EP (European Pharmacopoeia), or JP (Japanese Pharmacopoeia) standards is often required.
Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies like the FDA. A DMF contains detailed information about the manufacturing process, facilities, controls, and specifications of the API. Pharmaceutical companies manufacturing finished drug products can reference these DMFs in their drug applications, rather than having to submit all the proprietary manufacturing details themselves.
Inspections and Audits: Regulatory agencies conduct regular inspections of manufacturing facilities to verify GMP compliance. Pharmaceutical companies also conduct their own audits of API suppliers to ensure quality and reliability. These audits assess production processes, quality management systems, and adherence to specifications.
Pharmacopeial Standards: Methotrexate LPF must meet the specific purity, identity, strength, and quality requirements outlined in recognized pharmacopeias. This includes testing for impurities, assay, and physical characteristics.
Quality Control Testing: Manufacturers implement rigorous quality control measures at various stages of production. This includes testing of raw materials, in-process samples, and the final API. Tests typically include:
- Assay: To determine the concentration of Methotrexate LPF.
- Impurity Profiling: To identify and quantify any related substances or degradation products.
- Residual Solvents: To ensure that levels of residual solvents from the manufacturing process are within acceptable limits.
- Heavy Metals: To test for the presence of potentially toxic heavy metals.
- Microbiological Testing: For APIs intended for parenteral administration, although Methotrexate LPF is often formulated for oral or injectable use, microbial limits are critical.
- Particle Size Distribution: For APIs used in solid dosage forms or suspensions, particle size can impact bioavailability and formulation properties.

The regulatory status and the robustness of the quality control framework are critical determinants of supplier reliability and product acceptability. Suppliers with a history of successful regulatory inspections and strong quality systems are generally preferred.

WHAT ARE THE KEY CHALLENGES AND RISKS IN THE METHOTREXATE LPF SUPPLY CHAIN?

The Methotrexate LPF supply chain faces several interconnected challenges and risks that pharmaceutical companies must actively manage.

Supplier Concentration: Despite a number of manufacturers, the market for specialized APIs can become concentrated. If a significant portion of global supply originates from a few key players, any disruption at one of these facilities can have a widespread impact. For example, if a major Indian manufacturer faces an extended shutdown, global supply could be severely affected.
Price Volatility: The cost of Methotrexate LPF can fluctuate based on raw material costs, production efficiencies, market demand, and competitive pressures. Sudden price increases can impact the profitability of finished drug products and strain procurement budgets.
Quality Variations: While regulatory frameworks exist, subtle variations in manufacturing processes and quality control can lead to differences in API characteristics between suppliers. Pharmaceutical companies must ensure that APIs from different sources are bioequivalent and perform consistently in their formulations.
Intellectual Property (IP) and Patent Landscape: While Methotrexate itself is an old molecule and its basic patent protection has long expired, specific manufacturing processes, polymorphs, or novel formulations involving Methotrexate LPF may still be subject to patent protection. Understanding the IP landscape is crucial to avoid infringement. However, for the API itself, the primary concern is not patent expiry, but ensuring consistent quality and availability from reputable manufacturers.
Geopolitical and Trade Risks: As noted, political instability, trade wars, or new tariffs imposed by major economies can disrupt the flow of goods and increase costs. Reliance on suppliers in regions prone to such risks necessitates contingency planning.
Natural Disasters and Pandemics: Unforeseen events like earthquakes, floods, or global health crises (e.g., COVID-19) can cripple manufacturing operations and disrupt logistics. The COVID-19 pandemic highlighted the fragility of global supply chains, leading to shortages and increased lead times for many pharmaceutical ingredients.
Environmental, Social, and Governance (ESG) Compliance: Increasingly, pharmaceutical companies are scrutinizing their supply chains for ESG compliance. Manufacturers must demonstrate responsible environmental practices, fair labor conditions, and ethical governance. Failure in these areas can lead to reputational damage and supply disruptions if partners are forced to disengage from non-compliant suppliers.

STRATEGIC IMPLICATIONS FOR PHARMACEUTICAL COMPANIES

For pharmaceutical companies reliant on Methotrexate LPF, a proactive and diversified sourcing strategy is essential.

Dual/Multi-Sourcing: Establishing relationships with at least two, preferably more, qualified suppliers from different geographical regions can mitigate single-source dependency. This strategy provides a buffer against disruptions at any single supplier.
Supplier Auditing and Relationship Management: Regular, thorough audits of potential and existing suppliers are critical to ensure ongoing GMP compliance and quality. Building strong, collaborative relationships with key suppliers can foster transparency and enable early identification of potential issues.
Inventory Management: Maintaining adequate safety stock of Methotrexate LPF can help buffer against short-term supply disruptions. However, this must be balanced against the costs and risks of holding large inventories.
Geographical Diversification of Suppliers: Sourcing from manufacturers in different continents reduces the impact of regional geopolitical events or natural disasters.
Monitoring Regulatory and Market Trends: Staying informed about evolving regulatory requirements, changes in trade policies, and market dynamics related to Methotrexate LPF and its precursors is crucial for anticipating and responding to potential supply chain shifts.
Contractual Safeguards: Negotiating robust supply agreements with clear terms regarding quality, delivery timelines, pricing, and force majeure events is vital.

By meticulously analyzing the supply chain and implementing strategic sourcing practices, pharmaceutical companies can ensure the consistent availability of Methotrexate LPF, thereby safeguarding patient access to essential medicines.

KEY TAKEAWAYS

The global supply of Methotrexate LPF is primarily provided by manufacturers located in India, China, Turkey, Iran, the United States, and Japan.
Key suppliers include Cipla, Sun Pharma, Jubilant Life Sciences, Altan Pharmaceutical, Biopharm, Pharmarock, and others, with India being a dominant manufacturing hub.
Potential supply chain bottlenecks stem from raw material availability, stringent regulatory compliance, geopolitical instability, and logistical challenges.
Methotrexate LPF production is governed by rigorous GMP standards and pharmacopeial requirements, with DMFs playing a crucial role in regulatory submissions.
Pharmaceutical companies must adopt dual/multi-sourcing strategies, conduct thorough supplier audits, and maintain strong relationships to mitigate risks associated with supplier concentration, quality variations, and geopolitical instability.

FAQS

1. How can I verify the GMP compliance of a Methotrexate LPF supplier?

Verification involves reviewing their most recent inspection reports from major regulatory bodies (FDA, EMA, etc.), requesting a copy of their Drug Master File (DMF), and conducting on-site audits to assess their quality management systems and manufacturing processes.

2. What are the typical lead times for Methotrexate LPF orders?

Lead times can vary significantly but generally range from 8 to 16 weeks for established suppliers, depending on order volume, current production schedules, and existing inventory levels. Urgent orders may incur higher costs or require expedited shipping.

3. Are there alternative suppliers if my primary Methotrexate LPF manufacturer faces production issues?

Yes, maintaining a pre-qualified list of alternative suppliers from different geographical regions is a standard risk mitigation strategy. Due diligence on these alternative suppliers should be an ongoing process, not just initiated during a crisis.

4. What is the impact of the patent landscape on Methotrexate LPF sourcing?

As Methotrexate is an old drug, the active pharmaceutical ingredient itself is off-patent. However, specific patented manufacturing processes, novel crystalline forms, or advanced formulations could still be protected. Sourcing from generic API manufacturers typically focuses on established, non-infringing production methods.

5. How does raw material availability affect Methotrexate LPF supply?

The synthesis of Methotrexate LPF requires specific chemical intermediates. Disruptions in the supply of these precursor chemicals, often sourced from different global chemical manufacturers, can directly impact the production capacity and availability of Methotrexate LPF. Monitoring the supply chain for these intermediates is as critical as monitoring the API manufacturers themselves.

CITATIONS

[1] Altan Pharmaceutical. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Company Website] (Note: Specific URL for API portfolio would be required for precise citation)

[2] Biopharm. (n.d.). Products. Retrieved from [Company Website] (Note: Specific URL for Methotrexate LPF or API list would be required for precise citation)

[3] Cipla Limited. (n.d.). APIs. Retrieved from [Company Website] (Note: Specific URL for API portfolio would be required for precise citation)

[4] Pfizer Inc. (n.d.). API Manufacturing. Retrieved from [Company Website] (Note: Specific details on Methotrexate LPF manufacturing by Pfizer following Hospira acquisition would be required for precise citation)

[5] Jubilant Life Sciences. (n.d.). API Manufacturing. Retrieved from [Company Website] (Note: Specific URL for API portfolio would be required for precise citation)

[6] MSN Laboratories. (n.d.). Product Portfolio. Retrieved from [Company Website] (Note: Specific URL for API portfolio would be required for precise citation)

[7] Pharmarock. (n.d.). Products. Retrieved from [Company Website] (Note: Specific URL for Methotrexate LPF or API list would be required for precise citation)

[8] Sun Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from [Company Website] (Note: Specific URL for API portfolio would be required for precise citation)

[9] Takeda Pharmaceutical Company Limited. (n.d.). Manufacturing & Supply. Retrieved from [Company Website] (Note: Specific details on Methotrexate LPF API manufacturing by Takeda would be required for precise citation)

[10] United States Pharmacopeia. (Current Edition). Methotrexate. In United States Pharmacopeia and The National Formulary.

[11] European Pharmacopoeia. (Current Edition). Methotrexate. In European Pharmacopoeia.

[12] U.S. Food & Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website]

Suppliers and packagers for METHOTREXATE LPF